Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ANGLE's parsortix gets favourable peer review for use in therapy selection

"The incorporation of Parsortix in protocols for therapy selection has the potential to meet a key need in personalised medicine.
picture of blood sample
The University Medical Centre Hamburg-Eppendorf (UKE) published new research
ANGLE PLC’s (LON:AGL OTCQX:ANPCY) cancer cell collection technology has received another encouraging peer review in a leading scientific journal.
 
The University Medical Centre Hamburg-Eppendorf (UKE) published new research detailing the use of ANGLE's Parsortix system in the Clinical Chemistry journal.
 
ANGLE's chief executive, Andrew Newland, said: "This fourth peer-reviewed publication in a key scientific journal adds to the growing body of published evidence of 
Parsortix's superior performance as a liquid biopsy.  
 
"The incorporation of Parsortix in protocols for therapy selection has the potential to meet a key need in personalised medicine. 
 
“By facilitating the determination of which drugs will benefit individual patients and which will have little clinical benefit yet cause significant side effects, such protocols will also help reduce the burden on expensive healthcare resources."
 
Klaus Pantel, chairman, Department of Tumour Biology at UKE's Centre of Experimental Medicine, added: "We are excited about the new workflows utilising Parsortix to study multi marker profiles of single CTCs by low cost qPCR approaches.  
 
“The high expression levels of chemokines achieved with Parsortix offers the potential for its use in therapy selection for patients and we will be progressing further studies to determine specific applications."
View full AGL profile View Profile

ANGLE plc Timeline

Newswire
October 12 2017

Related Articles

Antibiotics
October 04 2017
US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land.
m&a icon of bug fish swallowing big fish
December 04 2017
It is paying an initial US$13mln for Vamousse, which it is acquiring from TyraTech, the AIM-listed developer of the range. This will be followed by a deferred pay-out of as much as US$4.5mln based on sales targets
test tubes filled with blood
November 02 2017
In all, 116 of the 200 patients with the life-threatening auto-immune disease have been through the 52-week process looking at the efficacy of Lupuzor

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use